The 1990s are understandably thought of as a golden age in the U.S. pharmaceutical industry: the average number of new molecular entities approved each year was one-third higher than in the 2000s the majority of these drugs were in mass-market, primary care
segments that resulted in blockbuster sales; and marketing regulations, were substantially relaxed.
| File | Action |
|---|---|
| US Pharmaceutical Utilization Plateau.pdf | Download |